Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Pulmatrix, Inc. (PULM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update"
05/12/2023 8-K Quarterly results
Docs: "Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update"
08/10/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmazole contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspergillosis PUR3100 IND submission planned for Q1 2022 with Ph1study start anticipated in Q2 2022 PUR1800 Ph1b study on track for top-line data in Q1 2022"
08/10/2021 8-K Quarterly results
Docs: "Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update"
05/11/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates"
08/07/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
11/01/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : August 5, 2019 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Reports Q2 2019 Results"
05/15/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : May 15, 2019 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Reports Q1 2019 Results"
02/19/2019 8-K Quarterly results
11/14/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : November 14, 2018 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Reports Q3 2018 Results"
08/03/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : August 3, 2018 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Reports Q2 2018 Results"
05/11/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Pulmatrix Reports Q1 2018 Results"
03/13/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : March 13, 2018 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline LEXINGTON, MA — Pulmatrix, Inc. today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. “The Company continues to advance its iSPERSE -based product candidates,” said Robert W. Clarke, Ph.D. , chief executive officer of Pulmatrix. “We expect Phase 1b data in mid-2018 on Pulmazole targeting fungal infections for severe asthma and cystic fibrosis patients. We also expect non-clinical safety data on PUR1800 in the second half of 2018.” Projected 2018 Milestones"
11/09/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT : November 9, 2017 PULMATRIX, INC. Delaware 001-36199 46-1821392 99 Hayden Avenue, Suite 390 Lexington, MA 02421 Registrant's telephone number, including area code: 357-2333 Not Applicable",
"Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole"
08/04/2017 8-K Quarterly results
Docs: "Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials Strengthened Board of Directors and Completed In-License Agreement"
05/05/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report
11/04/2016 8-K Quarterly results
Docs: "Investor Contact"
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/12/2015 8-K Quarterly results
Docs: "Pulmatrix Reports 3rd Quarter Results; Provides Update on Business & Development Pipeline"
08/14/2015 8-K Quarterly results
Docs: "Investor Contact"
11/13/2014 8-K Quarterly results
Docs: "Ruthigen Reports Fiscal Second Quarter 2015 Financial Results"
08/14/2014 8-K Quarterly results
Docs: "Ruthigen Reports Fiscal First Quarter 2015 Financial Results"
06/30/2014 8-K Quarterly results
Docs: "Ruthigen Reports Fourth Quarter and Fiscal Year 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy